At SeraNovo, our focus is on addressing the inherent challenges associated with the oral delivery of peptides. The therapeutic promise of peptides is well-recognized, offering high specificity and potency. However, their successful oral administration is hindered by several physiological barriers. Peptides are susceptible to enzymatic degradation in the gastrointestinal tract and face significant challenges in permeating the intestinal epithelium due to their large molecular size and hydrophilic nature.
Our eutectic solvent-based formulation technology is specifically designed to tackle these obstacles. By creating a protective and facilitating formulation, our approach enhances the stability of peptides against enzymatic breakdown and optimizes their absorption through the gastrointestinal tract, this results in improved oral bioavailability. The technology operates on the principle of creating a favourable microenvironment that maintains peptide integrity and facilitates a more efficient transit across the intestinal barrier.
In essence, SeraNovo's technology is an innovative solution aimed at redefining the bioavailability of oral peptides. By directly addressing the core issues of stability and permeability, we enhance the therapeutic potential of these molecules.
Our commitment is to the advancement of oral peptide delivery, focusing on a scientific approach that opens new pathways for treatment and improves patient outcomes.
With SeraNovo, the future of effective and accessible peptide-based therapies is within reach.
Benefits of PeptiDES platform